This study explored the effectiveness of Strattera in treating oppositional defiant disorder (ODD) alongside ADHD in children aged 6-12 years. Patients were randomly given either Strattera or a placebo for 8 weeks. The results showed that Strattera was better than placebo in reducing ODD symptoms during weeks 2 and 5, but not by week 8. For ADHD symptoms, Strattera consistently outperformed placebo, showing improvement in overall clinical functioning.

However, while Strattera helped with ADHD, its lasting effect on ODD symptoms was uncertain by the end of the study.

This study examined the effect of Strattera on ADHD symptoms in children with both ADHD and autism. Over 8 weeks, 97 patients received either Strattera or a placebo. Strattera reduced ADHD symptoms more than the placebo, especially in terms of hyperactivity. However, not significantly more patients on Strattera showed marked improvement overall according to the CGI-I scale.

Adverse events were reported in 81.3% of those on Strattera, similar to rates in previous studies. No serious adverse events occurred.

This study examined the effects of Strattera (atomoxetine) on behavior in adults with ADHD. Participants were given a single dose of Strattera, and their behavior was measured using tasks that assessed response inhibition and working memory. Compared to a placebo, Strattera led to improvements in inhibitory control, as seen by shorter reaction times and fewer errors on attention tasks. These findings indicate that Strattera may help improve certain behaviors linked to ADHD by enhancing brain function.

This review examined safety data for Strattera (atomoxetine) in treating ADHD, focusing on behavioral concerns like suicidality, aggression, and hostility. A meta-analysis showed no significant link between Strattera and suicidality, while aggression/hostility was slightly more frequent but still not statistically significant. Symptoms like psychosis and mania mainly appeared in those with existing mental health conditions.

The findings suggest that Strattera has a low risk of behavioral side effects in children and adolescents.

This abstract reviews multiple safety aspects of Strattera (atomoxetine) for children and adolescents with ADHD. It summarizes findings from 70 studies and reports on behavior-related issues, including suicidality and aggression. The data indicate that suicidality is rare with Strattera, and the frequency of aggression is similar to that of placebo-treated patients.

Psychosis and mania were mostly seen in patients with existing bipolar disorder or depression, suggesting these are not common side effects in the general ADHD population.

Strattera, known generically as atomoxetine, is utilized to manage ADHD symptoms by enhancing norepinephrine levels in the brain, which can bolster attention and lessen impulsivity. However, it carries the potential for significant behavioral changes, including positive effects like improved focus and adverse effects such as increased aggression or hostility.

Studies have highlighted severe risks, including suicidal thoughts and psychotic symptoms, necessitating vigilant monitoring, particularly in children and adolescents. Strattera is most effective as part of a comprehensive treatment plan that involves behavioral therapy and educational support, requiring consistent use and careful supervision to mitigate potential risks and maximize positive outcomes.